Clinical trial · Interventional
An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies
A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BG-75202, Alone and in Combination With Other Agents, in Patients With Myeloid Malignancies
NCT07619287CI-TRIAL-00122451recruitingPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260929-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of BG-75202 (KAT6A/B inhibitor) alone and in combination with other agents in patients with myeloid malignancies.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Myeloid Malignancy | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BG-75202 | Drug | — | UNRESOLVED |
| Hypomethylation Agent (HMA) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Phase 1a: Part A: Dose escalation, BG-75202 monotherapy
- description
- Sequential cohorts of increasing dose levels of BG-75202 will be evaluated as monotherapy.
- interventionNames
- Drug: BG-75202
- type
- EXPERIMENTAL
- label
- Phase 1a: Part B: Dose escalation, BG-75202 + Hypomethylation Agent (HMA)
- description
- Sequential cohorts of increasing dose levels of BG-75202 in combination with Hypomethylation Agent (HMA) will be evaluated.
- interventionNames
- Drug: BG-75202
- Drug: Hypomethylation Agent (HMA)
- type
- EXPERIMENTAL
- label
- Phase 1b: Dose optimization, BG-75202 monotherapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients must be ≥ 18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place), inclusive, at the time of signing the Informed consent form (ICF). * Patients must have a confirmed diagnosis of myeloid malignancies based on 2016 World Health Organization criteria, and meet the following categories: * Relapsed/refractory; myeloid malignancies after ≥1 prior systemic therapy, per ELN; 2022 criteria; patients with actionable genetic alteration must have previously received targeted therapies unless contraindicated, unavailable/inaccessible, or declined by patient. * Patients must have a stable Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2. Exclusion Criteria: * Prior exposure to KAT6A/B inhibitors/degraders. * A diagnosis of acute promyelocytic leukemia or BCR-ABL-positive leukemia. * Known central nervous system involvement by leukemia * Use of antileukemic therapies without sufficient washout period Note: Other protocol defined Inclusion/Exclusion criteria may apply.
References
Publications (0)
Data not yet available
No reference posted for this study.